A factor XIII activity test measures how well factor XIII works after a blood clot has already formed. Factor XIII helps strengthen the fibrin mesh that holds a clot together, so a person with low factor XIII often forms a clot at first but bleeds later when that clot breaks down too early. This is why routine clotting tests, including PT and aPTT, often look normal even when factor XIII deficiency is present.
Doctors usually order this test when bleeding is unusual, delayed, severe, or unexplained by standard coagulation results. Low factor XIII activity raises concern for an inherited deficiency, an acquired deficiency, an inhibitor, heavy consumption during illness or surgery, or reduced production from liver-related disease. The result matters most when interpreted with bleeding history, recent transfusions or factor treatment, pregnancy history, surgery plans, and other blood tests.
- Factor XIII activity usually has a normal range near 50% to 150% or higher, but each laboratory sets its own cutoff; some labs report normal as 55% or above.
- Low factor XIII activity mainly causes delayed bleeding, poor wound healing, large bruises or hematomas, umbilical stump bleeding in newborns, and recurrent pregnancy loss.
- PT, INR, aPTT, and thrombin time are usually normal in factor XIII deficiency because factor XIII acts after fibrin formation.
- Severe inherited factor XIII deficiency is often below 1% to 5% activity and carries a high risk of serious bleeding, including intracranial hemorrhage.
- Bleeding risk rises sharply at very low levels, especially below about 15% activity, but symptoms and treatment thresholds must be individualized.
- Recent plasma, cryoprecipitate, or factor XIII concentrate can falsely improve the result, so timing matters when testing for deficiency.
Table of Contents
- What the Factor XIII Activity Test Measures
- When Doctors Order a Factor XIII Activity Test
- Factor XIII Activity Normal Range and Result Levels
- What Low Factor XIII Activity Means
- Bleeding Risk, Symptoms, and Warning Signs
- Test Preparation, Sample Handling, and Timing
- Follow-Up Tests and Treatment Options
- How to Read Factor XIII Results in Context
What the Factor XIII Activity Test Measures
A factor XIII activity test measures the functional activity of coagulation factor XIII, a clotting protein that stabilizes a clot after fibrin has formed. Factor XIII is sometimes called the fibrin-stabilizing factor because its main job is to cross-link fibrin strands and make the clot stronger, tighter, and more resistant to early breakdown.
Blood clotting works in stages. First, platelets gather at the injured blood vessel. Then clotting proteins generate thrombin, which converts fibrinogen into fibrin. Fibrin forms a mesh around the platelet plug. Factor XIII then strengthens that mesh. Without enough working factor XIII, the body still produces a clot, but the clot lacks durability.
This explains one of the most confusing parts of factor XIII deficiency: routine clotting tests often look normal. A coagulation panel checks parts of clot formation, such as PT, INR, aPTT, fibrinogen, and D-dimer. These tests help diagnose many bleeding and clotting problems, but they do not reliably detect factor XIII deficiency because they stop measuring before factor XIII does its main work.
Factor XIII circulates in plasma mostly as a complex made from A subunits and B subunits. The A subunit performs the enzyme activity. The B subunit carries and protects the A subunit in the bloodstream. Inherited factor XIII deficiency usually involves the A subunit, though B subunit deficiency also occurs. Acquired deficiency happens later in life when factor XIII is consumed, diluted, underproduced, or blocked by antibodies.
A factor XIII activity result answers a specific question: how much working factor XIII activity is present in the plasma sample compared with normal pooled plasma? Results usually appear as a percentage, such as 65%, or as IU/dL, where 100 IU/dL roughly corresponds to 100% activity.
The activity test is more useful than a simple presence-or-absence test because bleeding risk relates to how much functional factor XIII remains. A person with very severe deficiency has a different risk profile from someone with mildly reduced activity after surgery, critical illness, or a recent transfusion.
When Doctors Order a Factor XIII Activity Test
Doctors order factor XIII activity testing when bleeding does not match routine test results. The test is especially important when someone has repeated or delayed bleeding while PT, INR, aPTT, platelet count, and fibrinogen results look normal or do not fully explain the bleeding.
Common reasons for testing include:
- Delayed bleeding 24 to 48 hours after surgery, dental work, trauma, childbirth, or circumcision
- Bleeding from the umbilical stump in a newborn
- Unexplained intracranial bleeding, especially in an infant or child
- Large soft-tissue bruises, muscle hematomas, or deep bleeding without a clear cause
- Poor wound healing or abnormal scar formation
- Recurrent miscarriage, especially early pregnancy loss
- Heavy menstrual bleeding with otherwise unrevealing clotting tests
- A known family history of factor XIII deficiency
- Follow-up monitoring in a person already diagnosed with factor XIII deficiency
- Evaluation for acquired deficiency in severe illness, major surgery, sepsis, trauma, or disseminated intravascular coagulation
Factor XIII testing is also useful before procedures in people with a known deficiency. Surgeons and hematologists use the result to decide whether factor XIII replacement is needed before surgery and whether the activity level is adequate afterward.
The test is not a general screening test for every bruise, nosebleed, or heavy period. More common causes usually get checked first, including platelet problems, von Willebrand disease, fibrinogen disorders, liver disease, medication effects, and vitamin K problems. If routine tests and clinical history point elsewhere, a doctor usually pursues those causes before factor XIII testing.
Factor XIII deficiency deserves attention when the bleeding pattern is delayed. For example, a person who bleeds immediately during surgery often has a different problem from someone whose operation seems controlled at first but develops a large wound hematoma the next day. Delayed bleeding is one of the strongest clues because factor XIII affects clot stability rather than the first formation of the clot.
Women and people who can become pregnant need careful evaluation when factor XIII deficiency is suspected. Factor XIII helps maintain pregnancy and supports normal tissue repair. Low activity has been linked with recurrent pregnancy loss and bleeding around delivery, so testing and treatment planning are especially important before conception, during pregnancy, and before delivery in known deficiency.
Factor XIII Activity Normal Range and Result Levels
Factor XIII activity is usually reported as a percentage of normal activity or as IU/dL. Many laboratories use a reference interval near 50% to 150%, 50% to 220%, or a lower cutoff such as 55% or above. The exact range varies by laboratory method, analyzer, calibration, and population used to establish the reference interval.
Use the range printed on the lab report first. A result of 52% might be low in one laboratory and near the lower limit in another. The medical meaning also changes with the reason for testing. A mildly low result during critical illness carries a different interpretation from the same value in a child with lifelong delayed bleeding and a family history of consanguinity.
| Factor XIII activity result | Common interpretation | Why it matters |
|---|---|---|
| Within the lab reference range, often about 50% or 55% and above | Factor XIII deficiency is less likely | Other causes of bleeding should be considered if symptoms continue |
| About 30% to 70% | Mild reduction or possible carrier-level range in some inherited cases | Many people have few symptoms, but bleeding history still matters |
| About 15% to 30% | Moderate reduction | Bleeding risk becomes more clinically important, especially with surgery, trauma, or childbirth |
| Below about 15% | Marked deficiency | Risk of spontaneous major bleeding rises, including serious internal bleeding |
| Below 1% to 5% | Severe factor XIII deficiency | High concern for severe inherited deficiency, neonatal bleeding, intracranial bleeding, and need for specialist care |
A normal factor XIII activity result makes clinically significant factor XIII deficiency less likely, especially if the sample was collected before treatment. It does not rule out every bleeding disorder. Platelet function disorders, von Willebrand disease, connective tissue disorders, medication effects, vascular causes, and other rare clotting disorders still need consideration when bleeding symptoms are strong.
A borderline or mildly low result needs repeat testing or follow-up when the result conflicts with the clinical picture. Factor XIII activity can fall temporarily during major illness, surgery, inflammation, liver disease, massive bleeding, or heavy transfusion. A borderline result also needs review for specimen quality and testing method.
A very low result is more concerning and usually requires hematology follow-up. Doctors often confirm it with repeat factor XIII activity testing, factor XIII antigen testing, A-subunit and B-subunit evaluation, inhibitor testing when acquired disease is possible, and sometimes genetic testing.
A high factor XIII activity result usually has less clear meaning than a low result. Laboratories focus on identifying deficiency because low activity causes bleeding risk. Higher activity has been studied in relation to clot structure, inflammation, and thrombosis, but a high result alone usually does not diagnose a clotting disorder. Doctors interpret it with the full clinical picture rather than treating the number by itself.
What Low Factor XIII Activity Means
Low factor XIII activity means the tested plasma has reduced ability to stabilize fibrin clots. The cause can be inherited or acquired. The level, age at onset, bleeding pattern, family history, and other laboratory results help separate these possibilities.
Inherited factor XIII deficiency
Inherited factor XIII deficiency is rare and usually follows an autosomal recessive pattern. A person typically needs two disease-causing gene variants, one inherited from each parent, to develop severe deficiency. Most severe inherited cases involve the F13A1 gene, which affects the factor XIII A subunit. Less often, F13B variants affect the B subunit.
Severe inherited deficiency often appears early in life. Classic clues include umbilical stump bleeding, delayed bleeding after circumcision, large bruises when a child begins to walk, muscle bleeding, poor wound healing, and intracranial bleeding. Some people are diagnosed later because routine clotting tests stay normal and the disorder is rare.
Milder inherited deficiency or carrier-level activity usually causes fewer symptoms. Some people have no major bleeding until surgery, trauma, childbirth, or another hemostatic challenge exposes the weakness in clot stability.
Acquired factor XIII deficiency
Acquired factor XIII deficiency develops later in life. It is generally more common than congenital deficiency in hospital settings, especially in adults with serious illness or major procedures.
Acquired causes include:
- Increased consumption during major surgery, trauma, sepsis, DIC, thrombosis, or severe inflammation
- Dilution from major bleeding, plasma exchange, or large-volume fluid and blood product resuscitation
- Reduced production or altered balance in liver disease or leukemia
- Autoimmune inhibitors that block factor XIII activity
- Certain medications reported in association with low factor XIII, including isoniazid, valproic acid, and tocilizumab
- Critical care settings, including extracorporeal membrane oxygenation and complex cardiac or trauma care
Low factor XIII in an adult with new unexplained bleeding deserves careful evaluation for acquired deficiency. Autoimmune acquired factor XIII deficiency is rare but serious. It often presents with large spontaneous bruises, muscle bleeding, soft-tissue bleeding, or postoperative bleeding. Inhibitor testing becomes important when factor XIII activity is very low, bleeding is severe, and there is no lifelong bleeding history.
Low factor XIII with other abnormal blood tests
Low factor XIII rarely stands alone in complex illness. If fibrinogen is low, platelets are low, D-dimer is high, PT or aPTT is prolonged, and the patient is acutely ill, the problem may involve broader coagulation activation or consumption. Fibrinogen testing is especially relevant because fibrin is the clot structure that factor XIII stabilizes; a fibrinogen blood test helps show whether the body has enough fibrinogen substrate for clot formation.
Liver disease can also affect clotting balance. The liver produces many coagulation proteins, and advanced liver disease can disturb both bleeding and clotting pathways. In that setting, factor XIII is one part of a wider assessment that often includes PT/INR, fibrinogen, platelet count, bilirubin, albumin, and liver enzymes. A liver function test panel helps place the coagulation result in context when reduced synthesis is suspected.
Bleeding Risk, Symptoms, and Warning Signs
Factor XIII deficiency causes bleeding because clots lack lasting strength. The first clot often forms normally, so the person may seem stable at first. Bleeding then returns hours or days later when the clot breaks down too soon.
Common symptoms linked with low factor XIII include:
- Delayed bleeding after injury, surgery, dental extraction, or childbirth
- Large bruises or deep hematomas
- Bleeding into muscles or joints
- Umbilical stump bleeding in newborns
- Poor wound healing
- Heavy menstrual bleeding
- Recurrent pregnancy loss
- Nosebleeds or gum bleeding in some people
- Intracranial bleeding, especially in severe deficiency
The most dangerous complication is bleeding in the brain or around the brain. Severe inherited factor XIII deficiency has a higher risk of intracranial hemorrhage than many other inherited bleeding disorders. This risk explains why confirmed severe deficiency is treated proactively rather than managed only after bleeding occurs.
Urgent medical care is needed for symptoms that suggest serious internal bleeding, including:
- Sudden severe headache
- Vomiting with headache or confusion
- Weakness, numbness, seizure, fainting, or trouble speaking
- Head injury in someone with known or suspected severe deficiency
- Rapidly enlarging bruise, swelling, or painful muscle tightness
- Blood in vomit, stool, or urine
- Heavy bleeding after surgery, childbirth, or trauma
- Newborn bleeding from the umbilical stump
The activity level helps estimate risk, but it does not replace clinical judgment. A person with factor XIII activity below 1% needs close specialist management even if bleeding is not active at that moment. A person with 40% activity and no bleeding history usually has a different risk. Surgery, pregnancy, childbirth, trauma, and anticoagulant use can shift the risk upward even when the baseline level is not severely low.
Bleeding history is often more informative than a single number. Doctors ask about timing, depth, and severity: Did bleeding happen right away or the next day? Did it require transfusion, surgery, or hospital care? Were there large muscle bleeds or only small bruises? Did family members have similar problems? These details help distinguish factor XIII deficiency from platelet disorders, von Willebrand disease, medication effects, and local surgical causes.
When symptoms point toward platelet or von Willebrand problems, doctors may add a von Willebrand disease panel or platelet function testing. Those tests evaluate earlier parts of clot formation that factor XIII activity testing does not measure.
Test Preparation, Sample Handling, and Timing
A factor XIII activity test usually requires a standard blood draw from a vein. Most people do not need to fast. The sample is collected into a citrate tube, which prevents the blood from clotting before the laboratory measures factor XIII activity.
Good sample handling matters. Factor XIII testing is specialized, and some laboratories send the sample to a reference lab. The plasma often needs prompt processing, proper centrifugation, freezing when required, and careful transport. Poor sample handling can distort results.
Before testing, tell the clinician or laboratory about:
- Recent plasma transfusion
- Cryoprecipitate
- Factor XIII concentrate
- Major bleeding or recent surgery
- Pregnancy or recent delivery
- Blood thinners, including heparin, warfarin, and direct oral anticoagulants
- Liver disease
- Autoimmune disease
- Current infection, sepsis, or critical illness
- Recent massive transfusion or plasma exchange
Recent treatment is one of the biggest interpretation problems. Plasma, cryoprecipitate, and factor XIII concentrate raise factor XIII activity and can hide an underlying deficiency. If the goal is diagnosis rather than treatment monitoring, the blood draw should ideally happen before replacement therapy. In emergencies, treatment should not wait just to preserve a clean diagnostic sample, but clinicians often try to collect blood before giving factor products when it is safe and practical.
Anticoagulants do not all affect factor XIII activity assays in the same way. Some assays tolerate heparin or other interfering substances better than others. The laboratory method matters, so doctors rely on the lab’s cautions when interpreting results in patients on anticoagulation.
Specimen quality also matters. Hemolysis, severe lipemia, high bilirubin, or residual platelets in processed plasma can interfere with some methods. If the result is surprising, repeating the test with careful collection and handling is reasonable.
Testing during acute illness needs special caution. Factor XIII can fall because of consumption, dilution, inflammation, or bleeding rather than a lifelong inherited problem. In that setting, a low result still matters because it may contribute to bleeding risk, but repeat testing after recovery helps show whether the deficiency persists.
Newborn testing requires a specialist approach. Severe congenital factor XIII deficiency can present early, but neonatal blood testing has special collection and interpretation challenges. A pediatric hematologist should guide testing when a newborn has umbilical stump bleeding, unexplained intracranial bleeding, or a family history of factor XIII deficiency.
Follow-Up Tests and Treatment Options
A low factor XIII activity result usually leads to more testing, especially when the result is clearly reduced or the bleeding history is concerning. The first goal is to confirm the deficiency. The second is to identify the type. The third is to decide whether treatment is needed for bleeding, prevention, surgery, pregnancy, or long-term protection.
Follow-up testing often includes:
- Repeat factor XIII activity test
- Factor XIII antigen testing
- Factor XIII A-subunit and B-subunit evaluation
- Inhibitor or autoantibody testing when acquired deficiency is suspected
- Genetic testing for inherited deficiency
- CBC and platelet count
- PT/INR and aPTT
- Fibrinogen activity and antigen when needed
- Thrombin time or reptilase time when fibrinogen problems are possible
- Liver and kidney assessment in complex illness
- DIC evaluation when the patient is acutely ill
A normal aPTT result does not exclude factor XIII deficiency. This point is important because many people with severe factor XIII deficiency have normal PT and aPTT, leading to delayed diagnosis.
Older clot solubility tests used urea or acid to see whether a clot dissolved too easily. These tests detect only very severe deficiency and miss many mild or moderate cases. Modern quantitative factor XIII activity assays are preferred when available. Clot solubility testing still appears in some settings because it is inexpensive, but a negative solubility test does not reliably rule out factor XIII deficiency.
Treatment depends on severity and cause. Confirmed severe congenital factor XIII deficiency is usually treated with factor XIII replacement to prevent spontaneous bleeding. Replacement products include plasma-derived factor XIII concentrate and recombinant factor XIII-A in appropriate patients. Fresh frozen plasma or cryoprecipitate may be used when specific factor XIII products are unavailable, but they carry broader transfusion considerations and are less targeted.
In acute bleeding, doctors treat based on bleeding severity, factor XIII level, product availability, body weight, and the suspected cause. Severe bleeding, head bleeding, major trauma, or surgical bleeding requires urgent hematology involvement.
Long-term prophylaxis is common in severe inherited deficiency because factor XIII has a relatively long half-life compared with many clotting factors. Dosing schedules differ by product and patient. Monitoring ensures the trough level stays high enough to reduce bleeding risk.
Pregnancy requires planned specialist care. Factor XIII supports placental stability, pregnancy maintenance, and hemostasis at delivery. People with known factor XIII deficiency need coordinated care from hematology and obstetrics before conception when possible, then monitoring and replacement planning during pregnancy and delivery.
Acquired factor XIII deficiency requires treatment of the underlying cause. When an inhibitor is present, care may include factor replacement for bleeding control plus immunosuppressive treatment to reduce antibody production. When low factor XIII results from consumption or dilution during surgery, trauma, or sepsis, treatment focuses on bleeding control, the underlying illness, and targeted replacement when clinically indicated.
Vitamin K does not correct factor XIII deficiency. Vitamin K supports factors II, VII, IX, and X, not factor XIII. A vitamin K blood test may be relevant when PT/INR is prolonged or vitamin K deficiency is suspected, but it does not replace factor XIII testing when delayed bleeding occurs with normal routine coagulation results.
How to Read Factor XIII Results in Context
A factor XIII activity result is most useful when read alongside the bleeding story. The same number has different meaning in a newborn with umbilical stump bleeding, an adult on extracorporeal support, a person recovering from major surgery, and someone tested because a relative has inherited deficiency.
Use these interpretation steps:
- Confirm the lab’s reference range. The lower limit varies by assay. Do not rely only on a generic normal range from another lab.
- Check whether treatment happened before the blood draw. Plasma, cryoprecipitate, or factor XIII concentrate can raise activity and mask deficiency.
- Compare the level with the bleeding pattern. Delayed bleeding with normal PT and aPTT fits factor XIII deficiency better than immediate surface bleeding alone.
- Look for acquired triggers. Surgery, sepsis, DIC, trauma, liver disease, autoimmune disease, and certain medications can lower factor XIII.
- Repeat or expand testing when the result is unexpected. Antigen testing, inhibitor testing, and genetic testing help clarify the diagnosis.
- Use specialist guidance for severe deficiency, pregnancy, surgery, or major bleeding. These settings require individualized targets and treatment planning.
Do not interpret a factor XIII activity test as a general “blood thickness” test. Low factor XIII does not mean the blood is thin in the same way as warfarin or heparin therapy. It means the fibrin clot may lack stability after it forms.
Do not assume normal PT and aPTT rule out dangerous bleeding disorders. Factor XIII deficiency is one of the classic examples of a serious bleeding disorder with normal screening coagulation tests. This is especially important after postoperative bleeding, recurrent pregnancy loss, umbilical stump bleeding, and unexplained intracranial bleeding.
Do not treat a mild low result without context. In hospitalized adults, factor XIII can fall during acute illness. A mild reduction may signal broader inflammation, consumption, dilution, or liver-related changes rather than inherited deficiency. The clinical situation determines whether the result needs urgent treatment, repeat testing, or outpatient follow-up.
Do not ignore a very low result. Factor XIII activity below 15% deserves prompt hematology review, and levels below 1% to 5% are highly concerning for severe deficiency. These levels carry real bleeding risk even when the person is not actively bleeding at the time of testing.
For patients, the most useful questions to ask after a low factor XIII result are direct:
- What was my exact factor XIII activity level and reference range?
- Was the sample collected before any plasma, cryoprecipitate, or factor XIII treatment?
- Do I need repeat activity testing or antigen testing?
- Is this more likely inherited or acquired?
- Do I need testing for a factor XIII inhibitor?
- Do I need treatment before surgery, dental work, pregnancy, or delivery?
- Should family members be tested?
- What symptoms should trigger urgent care?
Factor XIII activity testing fills an important gap in bleeding evaluation. It identifies a problem that routine coagulation tests often miss: weak clot stabilization after the clot has already formed. When the result is low and the bleeding pattern fits, the test can explain years of delayed bleeding, guide safe surgery and pregnancy planning, and prevent life-threatening complications through targeted specialist care.
References
- Factor XIII Deficiency: A Review of Biology, Testing, and Treatment 2026 (Review)
- Measurement of factor XIII for the diagnosis and management of deficiencies: insights from a retrospective review of 10 years of data on consecutive samples and patients 2025 (Study)
- Factor XIII Deficiency 2024 (Review)
- Coagulation Factor XIII (13) Activity Assay, Plasma 2026 (Laboratory Reference)
- Management of rare inherited bleeding disorders: Proposals of the French Reference Centre on Haemophilia and Rare Coagulation Disorders 2023 (Guideline)
- Minimal factor XIII activity level to prevent major spontaneous bleeds 2017 (Cohort Study)
Disclaimer
This article is for education only and does not replace care from a qualified healthcare professional. Factor XIII deficiency can cause serious bleeding even when routine clotting tests are normal, so low results, delayed bleeding, pregnancy concerns, newborn bleeding, or bleeding after surgery should be reviewed by a clinician or hematologist.
